Clinical Usefulness of Monitoring Cytomegalovirus-Specific Immunity by Quantiferon-CMV in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Cytomegalovirus (CMV) is a well-established cause of morbidity and mortality in pediatric recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). CD8+ T-cells are important for controlling CMV infection. We conducted a prospective pilot study to investigate the clinical utility of measuring the CMV-specific T-cell immune response using the QuantiFERON-CMV assay (QF-CMV) in pediatric allo-HSCT recipients. Overall, 16 of 25 (64%) patients developed CMV infection. QF-CMV was evaluated in these 16 patients during the early and late phases of the first CMV infection post allo-HSCT. Whereas the initial QF-CMV results during the early phase of CMV infection did not correlate with the course of the corresponding infection, the QF-CMV results post resolution of the first CMV infection correlated with the recurrence of CMV infection until 12 months post allo-HSCT; no recurrent infections occurred in the four QF-CMV-positive patients, while recurrent infections manifested in five of eight QF-CMV-negative (62.5%) and all three QF-CMV-indeterminate patients (P=0.019). In spite of the small number of patients examined, this study supports the potential application of monitoring CMV-specific T-cell immunity using the QF-CMV assay to predict the recurrence of CMV infection in pediatric allo-HSCT recipients.
Abstract
Cytomegalovirus (CMV) is a well-established cause of morbidity and mortality in pediatric recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). CD8+ T-cells are important for controlling CMV infection. We conducted a prospective pilot study to investigate the clinical utility of measuring the CMV-specific T-cell immune response using the QuantiFERON-CMV assay (QF-CMV) in pediatric allo-HSCT recipients. Overall, 16 of 25 (64%) patients developed CMV infection. QF-CMV was evaluated in these 16 patients during the early and late phases of the first CMV infection post allo-HSCT. Whereas the initial QF-CMV results during the early phase of CMV infection did not correlate with the course of the corresponding infection, the QF-CMV results post resolution of the first CMV infection correlated with the recurrence of CMV infection until 12 months post allo-HSCT; no recurrent infections occurred in the four QF-CMV-positive patients, while recurrent infections manifested in five of eight QF-CMV-negative (62.5%) and all three QF-CMV-indeterminate patients (P=0.019). In spite of the small number of patients examined, this study supports the potential application of monitoring CMV-specific T-cell immunity using the QF-CMV assay to predict the recurrence of CMV infection in pediatric allo-HSCT recipients.
참고문헌 (17)
- Hebart H, "Clinical aspects of CMV infection after stem cell transplantation", Hum Immunol, 65, pp.432~436 (2004)
- Castagnola E, "Cytomegalovirus infection after bone marrow transplantation in children", Hum Immunol, 65, pp.416~422 (2004)
- Ljungman P, "CMV infections after hematopoietic stem cell transplantation", Bone Marrow Transplant, 42(Sl), pp.S70~S72 (2008)
- Meijer E, "Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants", Clin Microbiol Rev, 16, pp.647~657 (2003)
- Goodrich JM, "Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant", Ann Intern Med, 118, pp.173~178 (1993)
- Goodrich JM, "Strategies for the prevention of cytomegalovirus disease after marrow transplantation", Clin Infect Dis, 19, pp.287~298 (1994)
- Boeckh M, "Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation", Pediatr Transplant, 8(S5), pp.S19~S27 (2004)
- Crough T, "Immunobiology of human cytomegalovirus: from bench to bedside", Clin Microbiol Rev, 22, pp.76~98 (2009)
- Harari A, "Cytomegalovirus (CMV)-specific cellular immune responses", Hum Immunol, 65, pp.500~506 (2004)
- Avetisyan G, "Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT", Bone Marrow Transplant, 40, pp.865~869 (2007)
- Walker S, "Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV", Transpl Infect Dis, 9, pp.165~170 (2007)
- Tey SK, "Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications", PLoS One, 8, pp.e74744~ (2013)
- Manuel O, "Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study", Clin Infect Dis, 56, pp.817~824 (2013)
- Lochmanova A, "Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation", Transplant Proc, 42, pp.3574~3577 (2010)
- Fleming T, "Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital", J Med Virol, 82, pp.433~440 (2010)
- Kumar D, "Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients", Am J Transplant, 9, pp.1214~1222 (2009)
- Abate D, "Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients", Transplantation, 93, pp.536~542 (2012)